title: PGPIPN, a therapeutic hexapeptide, suppressed human ovarian cancer growth by targeting BCL2.
abstract: Bioactive peptides, either derived from nature resources or synthesized by rational design, have been demonstrated potential for therapeutic agents against numerous human diseases, including cancer. However, the mechanism of therapeutic peptides against cancer has not been well elucidated. Here we show that PGPIPN, a hexapeptide derived from bovine β-casein, inhibited the proliferation of human ovarian cancer cells line SKOV(3) as well as the primary ovarian cancer cells in vitro. Consistently, PGPIPIN also decreased tumor growth rate in xenograft ovarian cancer model mice in a dose-dependent manner. Further study demonstrated that the anti-tumor effect of PGPIPN is partially through promoting cell apoptosis by inhibiting BCL2 pathway. Thus, our study suggests that PGPIPN is a potential therapeutic agent for the treatment of ovarian cancer or other types of cancer.
authors.affiliation: Department of Biochemistry & Molecular Biology, Anhui Medical University, Heifei, Anhui, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Fang
authors.initials: F
authors.lastname: Gu
authors.forename: Cai
authors.initials: C
authors.lastname: Wei
authors.forename: Yigui
authors.initials: Y
authors.lastname: Tang
authors.forename: Xin
authors.initials: X
authors.lastname: Zheng
authors.forename: Mingqiang
authors.initials: M
authors.lastname: Ren
authors.forename: Yide
authors.initials: Y
authors.lastname: Qin
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002364:Caseins / Q000737:chemistry; D002417:Cattle; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D006801:Humans; D051379:Mice; D058990:Molecular Targeted Therapy / Q000379:methods*; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
chemical_list: D002364:Caseins; D009842:Oligopeptides; D019253:Proto-Oncogene Proteins c-bcl-2